Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
RHB-56
- Development stage
- Preclinical
- Lead developer
- University of Maryland Eastern Shore
- Modality
- Small Molecules
01
Overview
RHB-56 (also known as RHB56) is a novel small molecule analog developed by researchers at the University of Maryland Eastern Shore as a potential anti-seizure agent for the treatment of epilepsy. Derived from the prototype lead compound IAA65, RHB-56 acts as an inhibitor of T-type voltage-gated calcium channels (T-VGCCs), specifically targeting the Ca_v 3.2 subunit. In vitro studies demonstrate that RHB-56 significantly reduces calcium currents generated by Ca_v 3.2 in a concentration-dependent manner by altering channel inactivation. The compound is undergoing preclinical evaluation in acute rodent seizure models to assess its efficacy and safety.
02
Targets
CACNA1H (T-type voltage-gated calcium channel 3.2)CACNA1I (Voltage-dependent T-type calcium channel subunit alpha-1I)
Beyond the preview
Go deeper on RHB-56.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on RHB-56.